Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory

被引:25
|
作者
Pati, Shibani [1 ]
Orsi, Sara A. [1 ]
Moore, Anthony N. [1 ]
Dash, Pramod K. [1 ]
机构
[1] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA
关键词
VEGF; Hippocampus; Long-term memory; Water maze; Neurogenesis; ENDOTHELIAL GROWTH-FACTOR; DORSAL HIPPOCAMPUS; IN-VITRO; NEUROGENESIS; KINASE; INHIBITOR; CASCADE; VIVO;
D O I
10.1016/j.brainres.2008.11.086
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A number of studies have established a role for vascular endothelial growth factor (VEGF) in angiogenesis. Recent reports have shown that VEGF overexpression in the hippocampus improves learning and memory and is associated with enhanced neurogenesis. PTK787/ZK222584 (PTK/ZK) is a reported inhibitor of VEGFR signaling that is currently being tested for its effects on lung and colon cancer. However, the influence of this drug on cognition has not been examined. In the present study, we questioned if post-training administration of PTK/ZK influences hippocampus-dependent memory. When administered to rats immediately following massed training in the Morris water maze, PTK/ZK impaired spatial memory retention tested 48 h later. This impairment was evidenced by increased latency to the hidden platform and fewer platform crossings. However, this impairment was not associated with a change in neurogenesis during this time frame. PTK/ZK infusion did not reduce VEGFR or AKT phosphorylation, but increased the phosphorylation of ERK. These studies suggest that VEGFR inhibitors such as PTK/ZK may negatively influence cognition. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 50 条
  • [1] PTK787/ZK222584, an inhibitor of VEGF receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, R
    Bendszus, M
    Wood, J
    Kiderlen, M
    Miebach, S
    Tonn, JC
    JOURNAL OF VASCULAR RESEARCH, 2004, 41 (01) : 96 - 96
  • [2] Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation
    Zips, D
    Krause, M
    Hessel, F
    Westphal, J
    Brüchner, K
    Eicheler, W
    Dörfler, A
    Grenman, R
    Petersen, C
    Haberey, M
    Baumann, M
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3869 - 3876
  • [3] The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase
    Banerjee, Susana
    Zvelebil, Marketa
    Furet, Pascal
    Mueller-Vieira, Ursula
    Evans, Dean B.
    Dowsett, Mitch
    Martin, Lesley-Ann
    CANCER RESEARCH, 2009, 69 (11) : 4716 - 4723
  • [4] The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy
    Banerjee, S. N.
    Thornhill, A.
    Evans, D. B.
    Littlewood-Evans, A. J.
    Dowsett, M.
    Martin, L-A
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S8 - S8
  • [5] Biomarkers (VEGF, BFGF) for assessing the biological activity of PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF
    Drevs, J
    Steward, WP
    Dugan, M
    Lee, L
    Laurent, D
    Zirrgiebel, U
    Yung, A
    Rich, J
    Unger, C
    Marme, D
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S78 - S78
  • [6] IN VITRO AND IN VIVO STUDIES REVEAL THAT THE VEGF-R INHIBITOR PTK787/ZK222584 IS A COMPETITIVE AROMATASE INHIBITOR
    Banerjee, S. N.
    Zvelebil, M.
    Furet, P.
    Mueller-Vieira, U.
    Dowsett, M.
    Evans, D.
    Martin, L.
    ANNALS OF ONCOLOGY, 2009, 20 : 61 - 61
  • [7] Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
    Schomber, Tibor
    Zumsteg, Adrian
    Strittmatter, Karin
    Crnic, Ivana
    Antoniadis, Helena
    Littlewood-Evans, Amanda
    Wood, Jeanette
    Christofori, Gerhard
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) : 55 - 63
  • [8] PTK787/ZK222584 Combined with Interferon Alpha and 5-Fluorouracil Synergistically Inhibits VEGF Signaling Pathway in Hepatocellular Carcinoma
    Katsura, Yoshiteru
    Wada, Hiroshi
    Murakami, Masahiro
    Akita, Hirofumi
    Hama, Naoki
    Kawamoto, Koichi
    Kobayashi, Shogo
    Marubashi, Shigeru
    Eguchi, Hidetoshi
    Tanemura, Masahiro
    Umeshita, Koji
    Doki, Yuichiro
    Mori, Masaki
    Nagano, Hiroaki
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S517 - S526
  • [9] PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, RH
    Bendszus, M
    Wood, J
    Kiderlen, M
    Sasaki, M
    Tonn, JC
    NEUROSURGERY, 2004, 55 (02) : 426 - 432
  • [10] A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas.
    George, D
    Jonasch, E
    Hart, L
    Lentz, J
    Parker, K
    Henry, A
    Pfister, C
    Dugan, M
    Laurent, D
    Clark, J
    Kaelin, WG
    Oh, W
    Kantoff, P
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3764S - 3764S